Related Experiment Videos
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions
P Natali1, M R Nicotra, R Cavaliere
1Department of Immunology, Regina Elena Cancer Institute, Rome, Italy.
Insights
Monoclonal antibody CL203.4 identifies intercellular adhesion molecule 1 (ICAM-1), a marker that is more reactive in malignant melanoma than benign lesions. Higher ICAM-1 expression in melanoma metastases correlates with poorer prognosis, suggesting its utility in melanoma staging.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Intercellular Adhesion Molecule 1 (ICAM-1) is a cell surface glycoprotein involved in immune responses.
- Monoclonal antibodies (MoAbs) are crucial tools for identifying specific cellular markers.
- ICAM-1's role in melanoma progression and metastasis is an area of active research.
Purpose of the Study:
- To characterize the reactivity of a novel monoclonal antibody, CL203.4, against ICAM-1.
- To investigate the expression patterns of ICAM-1 in benign and malignant melanocytic lesions.
- To determine the correlation between ICAM-1 expression and melanoma clinical parameters.
Main Methods:
- Immunochemical analysis using monoclonal antibody CL203.4.
- Immunohistochemical staining of surgically removed melanocytic lesions.
- Comparison of ICAM-1 expression in primary vs. metastatic melanoma and other malignancies.
- Correlation analysis between ICAM-1 reactivity and clinicopathological features (lesion thickness, clinical course).
Main Results:
- MoAb CL203.4 recognizes ICAM-1, with a distinct epitope from other anti-ICAM-1 antibodies.
- ICAM-1 expression was significantly lower in benign nevi compared to malignant melanomas.
- Metastatic melanomas showed higher ICAM-1 expression than primary melanomas, a unique finding among various cancers.
- ICAM-1 expression in stage I melanoma correlated significantly with lesion thickness and predicted a shorter disease-free interval.
Conclusions:
- ICAM-1, as detected by MoAb CL203.4, is differentially expressed in melanoma, with higher levels in malignant and metastatic lesions.
- Increased ICAM-1 expression in primary melanoma is associated with adverse clinical outcomes.
- ICAM-1 represents a potential biomarker for melanoma progression and prognosis.
Abstract:
Immunochemical studies have shown that the monoclonal antibody (MoAb) CL203.4, elicited with immune interferon treated cultured human melanoma cells Colo 38, recognizes intercellular adhesion molecule 1 (ICAM-1). The determinant defined by MoAb CL203.4 is distinct and spatially distant from that defined by anti-ICAM-1 MoAb RR1/1, which had been elicited with Epstein-Barr virus-transformed B-lymphocytes from a lymphocyte function associated antigen 1 deficient patient. Immunohistochemical testing with MoAb CL203.4 of surgically removed lesions of melanocyte origin has shown a markedly lower reactivity with benign than with malignant lesions. Among the latter, a higher percentage of metastatic than of primary lesions was stained by MoAb CL203.4. The higher expression of ICAM-1 in metastases than in primary lesions is unique to melanoma, since no difference was found in its distribution in primary and metastatic lesions of a variety of malignancies of different embryological origin. Reactivity with MoAb CL203.4 of primary lesions removed from patients with stage I melanoma showed a highly significant correlation with the lesion thickness and with the clinical course of the disease. The disease free interval in patients without detectable reactivity of their primary lesion with MoAb CL203.4 was significantly (P = 0.004) longer than that of patients whose primary lesion was stained with MoAb CL203.4. These results suggest that ICAM-1 may be a useful marker in the analysis of the molecular mechanism underlying the association between lesion thickness and clinical course of the disease.